As researchers consider using circulating tumor DNA as an endpoint in clinical trials to evaluate drug efficacy, a collaboration led by Friends of Cancer Research is creating the evidentiary roadmap for the use of ctDNA in regulatory decisions.
Setting cancer drug dosage used to be easy: find the delicate balance between killing the disease and subjecting the patient to intolerable harm, and you are done.
While overall cancer death rates have been dropping, the number of individuals being diagnosed with cancer has been going up, with younger patients increasingly affected.
A survey conducted by the National Comprehensive Cancer Network found that 93% of its 27 member institutions are experiencing shortages of carboplatin, and 70% lack cisplatin.
For over 30 years, radiation therapy has been a part of the standard of care for locally advanced rectal cancer patients.
NCI and all five cooperative groups that make up the National Clinical Trials Network have launched a large-scale precision medicine initiative that will match cancer patients with early-phase clinical trials testing novel drug combinations that target specific tumor alterations.
Proven curative regimens containing platinum-based drugs—cisplatin and carboplatin—have become largely unavailable because of a nationwide drug shortage. The institutions that have some supplies of cisplatin and carboplatin are setting up algorithms for rationing their dwindling stocks, which usually means giving top priority to patients treated with curative intent and denying standard-of-care treatment to patients who cannot be cured but who can still benefit from these drugs.
CAR T-cell therapies have been used to treat cancer patients since 2011, but infection-related adverse events remain a significant hurdle. Often, fever is one of the earliest warning signs of clinical deterioration and a potentially life-threatening condition.
To provide a roadmap for accelerating progress against breast cancer over the next 10 years, an expert panel was convened at the 2022 San Antonio Breast Cancer Symposium to identify the biggest obstacles hindering our ability to cure breast cancer and to propose transformative solutions to address these obstacles.
Pragmatica-Lung, the first study born from a broader effort by NCI, FDA, industry, academia, and advocacy groups to modernize the clinical trial process, has begun enrolling patients.
